Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Surviving Trump's ‘whack-a-mole’ tariffs
Markets

Brian Robins: Surviving Trump's ‘whack-a-mole’ tariffs

Trump's end game is to curtail China's trade position.

NZ sharemarket up nearly 0.5%, third rise this week
Markets Market Close

NZ sharemarket up nearly 0.5%, third rise this week

The S&P/NZX 50 Index gained 56.99 points or 0.44% to 13,000.56.

Graham Skellern 16 Jan 2025
NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Graham Skellern 15 Jan 2025
Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

Staff reporters 15 Jan 2025